Mark Dant speaks with host Stephanie Cozine about his experiences after his son, Ryan, was diagnosed with MPS I. Mark discusses the impact of The Ryan Foundation in the development of the enzyme replacement therapy Aldurazyme, the first and only FDA-approved treatment for MPS I. He shares of a specific moment that sparked his urgency to change the course for those with rare diseases.
